Congenital heart disease-associated pulmonary hypertension

EB Rosenzweig, U Krishnan - Clinics in Chest Medicine, 2021 - chestmed.theclinics.com
Data from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension
Disease Management (REVEAL) and the French registry estimate the prevalence of …

Pharmacological therapy in adult congenital heart disease: growing need, yet limited evidence

M Brida, GP Diller, H Nashat, M Strozzi… - European Heart …, 2019 - academic.oup.com
Congenital heart disease (CHD) is the most common inborn defect. Due to advances in
paediatric care, surgical, and catheter procedures the number of adults with CHD has grown …

Cannabis induced cardiac arrhythmias: a case series

E Yahud, G Paul, M Rahkovich… - … Heart Journal-Case …, 2020 - academic.oup.com
Introduction Cannabis use is known to be associated with significant cardiovascular
morbidity. We describe three cases of cannabis-related malignant arrhythmias, who …

Lumpers and splitters: the bumpy road to precision medicine

TF Lüscher - European Heart Journal, 2019 - academic.oup.com
The eminent cardiologist Attilio Maseri once said that there are lumpers and splitters in
medicine. As an example he argued that anaemia has many different phenotypes and …

Preventing disease progression in Eisenmenger syndrome

A Barradas-Pires, A Constantine… - Expert Review of …, 2021 - Taylor & Francis
Introduction: Eisenmenger syndrome describes a condition in which a congenital heart
defect has caused severe pulmonary vascular disease, resulting in reversed (right-left) or …

Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management

M Papamichalis, A Xanthopoulos, P Papamichalis… - Heart Failure …, 2020 - Springer
Adult congenital heart disease (ACHD) encompasses a range of structural cardiac
abnormalities present before birth attributable to abnormal foetal cardiac development. The …

Strategies for the management of pulmonary arterial hypertension in patients with congenital heart disease

N Liew, Z Rashid, R Tulloh - Journal of Congenital Cardiology, 2020 - Springer
Background Pulmonary hypertension (PH) is commonly seen in adults who have congenital
heart disease (CHD). Therapy is available for pulmonary arterial hypertension (PAH) and …

[HTML][HTML] Доказательная база специфических легочных вазодилататоров у взрослых с врожденными пороками сердца

АА Шмальц, СВ Горбачевский - Терапевтический архив, 2021 - cyberleninka.ru
После рассмотрения современных определений и классификации легочной
гипертензии (ЛГ), ассоциированной с врожденными пороками сердца (ВПС), на основе …

[PDF][PDF] Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series

S Blissett, D Blusztein… - European Heart Journal …, 2020 - academic.oup.com
Background There are significant risks of parenteral prostacyclin use in patients with
pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) …

Use of the prostacyclin receptor agonist selexipag in patients with pulmonary arterial hypertension associated with eisenmenger syndrome

EA Demerouti, P Karyofyllis… - Canadian Journal of …, 2021 - Elsevier
Eisenmenger syndrome is a multisystem disorder and the most severe form of pulmonary
arterial hypertension in adult congenital heart disease. Pulmonary arterial hypertension …